# REGN5381 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/regn5381

> REGN5381, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | REGN5381 |
| Codes | REGN5381 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Uncontrolled Hypertension](https://sec-api.dev/indications/uncontrolled-hypertension), [Heart Failure](https://sec-api.dev/indications/heart-failure) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Heart Failure.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." https://clinicaltrials.gov/study/NCT05353166

### September 17, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Heart Failure.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06237309 (REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06237309

### October 15, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Uncontrolled Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06833190 (REGN5381 in Adult Participants With Uncontrolled Hypertension): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06833190

### September 29, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Heart Failure.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." https://clinicaltrials.gov/study/NCT05353166?tab=results

## Same indication

- [Baxfendy (baxdrostat)](https://sec-api.dev/pdufa/baxdrostat) (AZN)
- [Baxdrostat and dapagliflozin](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) (AZN)
- [BMS-986435](https://sec-api.dev/pdufa/bms-986435) (BMY)
- [CDR132L](https://sec-api.dev/pdufa/cdr132l) (NVO)
- [Low dose pf-07328948](https://sec-api.dev/pdufa/low-dose-pf-07328948) (PFE)
- [Omecamtiv mecarbil (om)](https://sec-api.dev/pdufa/omecamtiv-mecarbil-om) (CYTK)
- [RTN-001](https://sec-api.dev/pdufa/rtn-001) (RTSN)
- [Verquvo (vericiguat)](https://sec-api.dev/pdufa/vericiguat) (MRK)
- [Ziltivekimab](https://sec-api.dev/pdufa/ziltivekimab) (NVO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/regn5381.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REGN5381 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/regn5381

```bibtex
@misc{secapidev_pdufa_regn5381_20261116,
  title        = {REGN5381 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/regn5381}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_regn5381_20261116","title":"REGN5381 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/regn5381","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
